Patient-centric trials for therapeutic development in precision oncology

Andrew V. Biankin; Steven Piantadosi; Simon J. Hollingsworth

doi:10.1038/nature15819

Patient-centric trials for therapeutic development in precision oncology

Andrew V. Biankin, Steven Piantadosi, Simon J. Hollingsworth

Research output: Contribution to journal › Review article › peer-review

187 Scopus citations

Abstract

An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours. Considerable associated challenges include how to advance and implement targeted drug-development strategies. Precision medicine centres on delivering the most appropriate therapy to a patient on the basis of clinical and molecular features of their disease. The development of therapeutic agents that target molecular mechanisms is driving innovation in clinical-trial strategies. Although progress has been made, modifications to existing core paradigms in oncology drug development will be required to realize fully the promise of precision medicine.

Original language	English (US)
Pages (from-to)	361-370
Number of pages	10
Journal	Nature
Volume	526
Issue number	7573
DOIs	https://doi.org/10.1038/nature15819
State	Published - Oct 14 2015

ASJC Scopus subject areas

General

Access to Document

10.1038/nature15819

Cite this

@article{6259984f57fc4e9d9ddf5764747e3911,

title = "Patient-centric trials for therapeutic development in precision oncology",

abstract = "An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours. Considerable associated challenges include how to advance and implement targeted drug-development strategies. Precision medicine centres on delivering the most appropriate therapy to a patient on the basis of clinical and molecular features of their disease. The development of therapeutic agents that target molecular mechanisms is driving innovation in clinical-trial strategies. Although progress has been made, modifications to existing core paradigms in oncology drug development will be required to realize fully the promise of precision medicine.",

author = "Biankin, {Andrew V.} and Steven Piantadosi and Hollingsworth, {Simon J.}",

year = "2015",

month = oct,

day = "14",

doi = "10.1038/nature15819",

language = "English (US)",

volume = "526",

pages = "361--370",

journal = "Nature",

issn = "0028-0836",

publisher = "Nature Research",

number = "7573",

}

TY - JOUR

T1 - Patient-centric trials for therapeutic development in precision oncology

AU - Biankin, Andrew V.

AU - Piantadosi, Steven

AU - Hollingsworth, Simon J.

PY - 2015/10/14

Y1 - 2015/10/14

N2 - An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours. Considerable associated challenges include how to advance and implement targeted drug-development strategies. Precision medicine centres on delivering the most appropriate therapy to a patient on the basis of clinical and molecular features of their disease. The development of therapeutic agents that target molecular mechanisms is driving innovation in clinical-trial strategies. Although progress has been made, modifications to existing core paradigms in oncology drug development will be required to realize fully the promise of precision medicine.

AB - An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours. Considerable associated challenges include how to advance and implement targeted drug-development strategies. Precision medicine centres on delivering the most appropriate therapy to a patient on the basis of clinical and molecular features of their disease. The development of therapeutic agents that target molecular mechanisms is driving innovation in clinical-trial strategies. Although progress has been made, modifications to existing core paradigms in oncology drug development will be required to realize fully the promise of precision medicine.

UR - http://www.scopus.com/inward/record.url?scp=84944316022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944316022&partnerID=8YFLogxK

U2 - 10.1038/nature15819

DO - 10.1038/nature15819

M3 - Review article

C2 - 26469047

AN - SCOPUS:84944316022

SN - 0028-0836

VL - 526

SP - 361

EP - 370

JO - Nature

JF - Nature

IS - 7573

ER -

Patient-centric trials for therapeutic development in precision oncology

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this